22 results about "Epstein–Barr virus" patented technology

This disclosure relates to fusion proteins comprising one or more EBV polypeptides and a ferritin protein, and their use in eliciting antibodies against EBV.

The present invention relates to vaccines based on viral vectors for delivery of antigens against infectious diseases. In particular, the present invention relates to a recombinantly modified vaccinia virus Ankara (MVA) encoding EBV antigens that elicit infectious mononuclear hyperplasia (IM) and different cancer types. The invention also relates to medical application of the recombinant MVA in prevention of diseases caused by EBV (Epstein-Barr Virus).

Herpesviridae glycoprotein B (gB) polypeptides comprising a modified ectodomain is stabilized in the prefusion state, enabling development of inhibitors and vaccines directed against these viral pathogens. Modifications to DI, DII, and DV subdomains are important to stabilization of gB in the prefusion state, and additional modifications result in a further improved stabilization of gB in the prefusion state. The gB can be derived from an Epstein Barr Virus (EBV), a Human Cytomegalovirus (CMV), a Human Herpesvirus 6 (HHV6), a Herpes Simplex Virus 1 (HSV1), or a Varicella Zoster Virus (VZV). Polypeptides, nucleic acid constructs, compositions, and methods of using same to elicit an immune response are described.

The present disclosure provides a vaccine composition that comprises an Epstein Barr Virus (EBV) polypeptide and a liposomal adjuvant, and methods of inducing an immune response to an Epstein Barr Virus (EBV) or methods of preventing infection of or reducing the likelihood of infection by an Epstein Barr Virus (EBV) using the compositions, or a combination of the EBV polypeptide and the liposomal adjuvant.

The invention provides methods and materials for the preparation of immune cells, including T cells engineered to express exogenous T cell receptors that target polypeptides associated with human leukocyte antigens. Embodiments of the invention include polynucleotides encoding T cell receptors that target human MEAF6 and SCAMP3 polypeptides, and engineered T cells transduced with these polynucleotides. Embodiments of the invention include polynucleotides encoding T cell receptors that target cytomegalovirus and Epstein Barr virus polypeptides, and engineered T cells transduced with these polynucleotides. Embodiments of the invention also include methods of making and using such polynucleotides and engineered T cells.

This disclosure relates to antigenic EBV polypeptides and their use in eliciting antibodies against EBV. Also disclosed are antigenic polypeptides comprising an EBV polypeptide and a ferritin protein.

This disclosure relates to fusion proteins comprising one or more EBV polypeptides and a ferritin protein, and their use in eliciting antibodies against EBV.

Provided herein are compositions comprising Epstein-Barr Virus envelope proteins (e.g., glycoprotein 350 (gp350)) and saponin adjuvant and methods of using the aforementioned compositions for inducing an immune response against Epstein-Barr Virus.

To provide methods for generating / expanding populations of immune cells comprising immune cells specific for an Epstein Barr Virus (EBV) lytic antigen.SOLUTION: The present invention provides methods comprising stimulating immune cells specific for an EBV lytic antigen by contacting peripheral blood mononuclear cells (PBMCs) with: (i) one or more peptides corresponding to all or part of one or more EBV lytic antigens; or (ii) antigen presenting cells (APCs) presenting one or more peptides corresponding to all or part of one or more EBV lytic antigens. Also disclosed are populations of immune cells comprising immune cells specific for an EBV lytic antigen expanded according to such methods, and uses thereof.SELECTED DRAWING: Figure 1A

Compositions and methods for treating a viral condition. The composition is administered to the subject in a therapeutic amount. The composition includes a first medicament effective for up-regulating disulfide bond donation and exchange, and a second medicament comprising a DNA polymerase inhibitor, a protease inhibitor, a DNA / RNA inhibitor, an intron splicer, or combinations thereof. The first medicament is effective for causing viruses to dissociate from integration sites and actively replicate with availability of disulfide bonds. The second medicament is effective for supporting or improving degradation, slicing, and / or inhibition of viral RNA, viral DNA, and / or viral proteins. The virus is Coronavirus, Epstein Barr virus, human papillomavirus, or herpes simplex virus.

Disclosed are compositions, methods, and kits that can be used to Epstein-Ban virus (EBV) in a sample undergoing testing. Nucleic acids of EBV can be isolated, amplified and detected with specificity by real-time PCR, and without interference from non-EBV organisms. In some embodiments, nucleic acids used for amplification are isolated from human blood, or blood products. Nucleic acid isolation, amplification and detection steps can all be carried out using an automated instrument.

This disclosure relates to fusion proteins comprising one or more EBV polypeptides and a ferritin protein, and their use in eliciting antibodies against EBV.

The present disclosure provides, a vaccine composition that comprises an Epstein Barr Virus (EBV) polypeptide and a squalene nanoemulsion (SNE) adjuvant, and methods of inducing an immune response to an Epstein Barr Virus (EBV) or methods of preventing infection of or reducing the likelihood of infection by an Epstein Barr Virus (EBV) using the compositions, or a combination of the EBV polypeptide and the SNE adjuvant.

Methods for the rapid detection of the presence or absence of Epstein Barr Virus (EBV) in a biological or non-biological sample are described. The methods can include performing an amplifying step, a hybridizing step, and a detecting step. Furthermore, primers and probes targeting EBV, and kits are provided that are designed for the detection of target regions of EBV. Also described are kits, reaction mixtures, and oligonucleotides (e.g., primer and probe) for the amplification and detection of EBV. Also described are primers and probes that detect different regions of EBV, and can be employed in a dual target assay for simultaneously detecting two different and non-overlapping target regions of EBV.

An isolated trifunctional bispecific antibody for use in a method of treating a patient suffering from a disease and / or disorder associated with reactivation of Epstein-Barr virus (EBV) in at least B cells and potentially other susceptible cells, such as susceptible epithelial cells, the method comprising: providing an autologous cell preparation of enriched B cells of the patient; incubating the enriched B cells with a trifunctional bispecific antibody for a period of time sufficient to establish a physical interaction between the trifunctional bispecific antibody and the enriched B cells to obtain an incubation mixture; transferring the incubation mixture obtained after incubation into the same patient, wherein the trifunctional bispecific antibody comprises: (a) a first binding arm binding to B cells via a B cell surface antigen; (b) a second binding arm binding to T cells via a T cell surface antigen; (c) an Fc part binding to Fc receptor positive cells. The invention also discloses a pharmaceutical composition comprising the isolated trifunctional bispecific antibody for use in treating a patient suffering from a disease and / or disorder associated with reactivation of EBV in B cells, and an ex vivo method for the preparation of the pharmaceutical composition.

The present invention provides a computer implemented method for predicting the risk of posttransplant lymphoproliferative disorder as well as a computer implemented method for simultaneous predicting the risk of posttransplant lymphoproliferative disorder and differentiation of Epstein Barr Virus (EBV)-positive from EBV-negative patients in posttransplant lymphoproliferative disorder and associated systems. The method for predicting the risk of posttransplant lymphoproliferative disorder PTLD, comprises the following steps: receiving information representative for expression level of biomarkers, acquired from a sample to be assessed, said biomarkers being at least three selected from the group comprising HSPA6, CD300A, IFITM1, SHFL, HMGB1, TMEM163, ELL3, GRHPR, GMDS, GALNT10, IRF1-AS1, IFIT5, MLLT3, KIR2DL4, CD1C, SP3, SLC6A16, COP1, classifying said information representative for expression level of said at least three biomarkers, outputting the classification results, said results being indicative of whether the assessed sample belongs to one of two classes: PTLD or non-PTLD patient. The present invention provides further biomarkers for predicting, diagnosing and differentiating of posttransplant lymphoproliferative disorders and use thereof.

The present disclosure relates to T cells specific to Epstein-Barr virus (EBV), particularly rejuvenated T cells (rejT) that allow allogeneic administration.

The present invention relates to a pharmaceutical composition for preventing or treating NK-T cell lymphoma comprising a phosphodiesterase 5 inhibitor, a composition for auxiliary anticancer treatment and a health functional food, which inhibits the reactivation of Epstein barr virus (EBV) caused by histone deacetylase (HDAC) inhibitors. Using the pharmaceutical composition for preventing, improving or treating NK-T cell lymphoma of the present invention, the side effects of HDAC inhibitors can be reduced by inhibiting the reactivation of Epstein barr virus caused by HDAC inhibitors used as NK-T cell lymphoma anticancer drugs, thereby significantly improving the anticancer effect. Therefore, based on the above effects, the present invention can be widely used in the field of medicine.

A recombinant, humanized antibody or antibody fragment that is capable of at least partly preventing or inhibiting Epstein Barr Virus gp350 binding to a human cell. The antibody may be useful for passively immunizing humans against Epstein Barr Virus and / or treating or preventing Epstein Barr Virus-associated diseases, disorders or conditions. The antibody or antibody fragment may also be used to detect Epstein Barr Virus.

Provided herein are methods comprising autologous cytotoxic T cells expressing a T cell receptor that specifically binds to an Epstein Barr virus (EBV) or expressing CD107a, TNF, IFN-gamma or IL-2 for the treatment of multiple sclerosis in a subject or selecting a subject for adoptive immunotherapy.

This application relates to variants of Epstein-Barr virus glycoprotein B and nucleic acids, such as messenger ribonucleic acids (mRNAs), encoding the same, as well as compositions comprising the same, vaccines comprising the same, and methods of using the same, such as in the prevention and / or treatment of diseases or conditions caused by Epstein-Barr virus.

The present invention is directed to novel dioxolane-derived 7-deazapurine nucleoside analogs, the antiviral activity of these compounds, pharmaceutical compositions thereof and methods of treating Epstein Barr Virus (EBV), Human Immunodeficiency Virus (HIV) infections and Multiple Sclerosis or reducing the likelihood of these disease states occurring in patients or subjects at risk for same, and inhibiting, resolving or ameliorating symptoms associated therewith.